These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2571713)

  • 21. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
    Bacopoulos NG
    J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain.
    Lappalainen J; Hietala J; Koulu M; Seppälä T; Sjöholm B; Syvälahti E
    J Pharmacol Exp Ther; 1990 Feb; 252(2):845-52. PubMed ID: 2179533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations.
    Levant B; Bissette G; Davis MD; Heffner TG; Nemeroff CB
    Synapse; 1991 Nov; 9(3):225-30. PubMed ID: 1685600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
    Meltzer LT; Christoffersen CL; Corbin AE; Ninteman FW; Serpa KA; Wiley JN; Wise LD; Heffner TG
    J Pharmacol Exp Ther; 1995 Aug; 274(2):912-20. PubMed ID: 7636754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
    Saller CF; Czupryna MJ; Salama AI
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of haloperidol decanoate, a long-acting neuroleptic, in behavioral and biochemical tests.
    Oka M; Karasawa T; Ochi Y; Asano K; Terauchi Y; Kadokawa T
    Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):289-302. PubMed ID: 4062440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison between some biochemical and behavioural effects produced by neuroleptics.
    Fregnan GB; Porta R
    Arzneimittelforschung; 1981; 31(1):70-4. PubMed ID: 6111328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
    Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine.
    Meltzer HY; Chai BL; Thompson PA; Yamamoto BK
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1452-61. PubMed ID: 8138957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization.
    Auth F; Kiss B; Laszlovszky I; Lapis E
    Pol J Pharmacol Pharm; 1988; 40(6):603-11. PubMed ID: 2479935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity.
    Goldstein JM; Litwin LC; Sutton EB; Malick JB
    J Pharmacol Exp Ther; 1989 Jun; 249(3):673-80. PubMed ID: 2567348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurochemical and behavioral studies on the mode of action of oxypertine.
    Moroji T; Okuyama T; Hagino Y; Sekiguchi R
    Arzneimittelforschung; 1986 May; 36(5):804-8. PubMed ID: 2873819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of systemic and intracerebroventricular domperidone treatment on striatal and hypothalamic dopaminergic neurons.
    Ferretti C; Benfenati F; Cimino M; Vantini G; Lipartiti M; Muccioli G; di Carlo R; Algeri S
    Med Biol; 1983; 61(6):331-6. PubMed ID: 6676604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders.
    Mitsushio H; Takashima M; Mataga N; Toru M
    J Pharmacol Exp Ther; 1988 Jun; 245(3):982-9. PubMed ID: 2455042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.